Related Experiment Video
Updated: Aug 13, 2026

Lateral Chronic Cranial Window Preparation Enables In Vivo Observation Following Distal Middle Cerebral Artery Occlusion in Mice
Published on: December 29, 2016
Nitrone spin on cerebral ischemia
1Division of Health Practice, Auckland University of Technology-Akoranga Campus, 90 Akoranga Drive, Northcote, Auckland, New Zealand. s.doggrell@xtra.co.nz
Abstract:
Clinical trials with radical scavenging antioxidants have shown little or no benefit in the treatment of ischemic stroke. The spin trap nitrones covalently bind with short-lived reactive radicals to inactivate them for longer than the conventional scavenging antioxidants. One of these agents, NXY-059, is effective in animal models of cerebral ischemia, and is in phase III clinical trials for ischemic stroke by AstraZeneca, under license from Renovis. Second-generation nitrones (azulenyl nitrones) have also been described and shown to be neuroprotective in animal models. Thus, at last, it seems that antioxidants that are potent enough to have considerable potential for the treatment of cerebral ischemia are in development.
Insights
New antioxidants called nitrones show promise for treating ischemic stroke, unlike older antioxidants. These spin traps effectively neutralize harmful radicals, offering hope for neuroprotection in cerebral ischemia treatment.
Area of Science:
- Neuroscience
- Pharmacology
- Biochemistry
Background:
- Radical scavenging antioxidants have yielded limited success in treating ischemic stroke.
- Reactive radicals play a significant role in the pathophysiology of cerebral ischemia.
Purpose of the Study:
- To evaluate the potential of spin trap nitrones as a novel therapeutic strategy for ischemic stroke.
- To highlight the development of second-generation nitrones with enhanced neuroprotective properties.
Main Methods:
- Investigated the mechanism of action of spin trap nitrones in covalently binding and inactivating reactive radicals.
- Reviewed efficacy of NXY-059 in animal models of cerebral ischemia.
- Examined neuroprotective effects of second-generation azulenyl nitrones in preclinical models.
Main Results:
- Spin trap nitrones demonstrate a more sustained inactivation of reactive radicals compared to conventional antioxidants.
- NXY-059 has shown efficacy in animal models and is currently in Phase III clinical trials for ischemic stroke.
- Second-generation nitrones exhibit significant neuroprotective capabilities in animal studies.
Conclusions:
- Spin trap nitrones represent a promising class of antioxidants for the treatment of cerebral ischemia.
- The development of potent antioxidants like NXY-059 and second-generation nitrones offers significant therapeutic potential for ischemic stroke.
Related Concept Videos
Ischemic Stroke ll: Pathophysiology
Transient Ischemic Attack l: Introduction
Ischemic Stroke l: Introduction

